Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.46 |
| ▸ | F2 | P00734 | 3/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
| ▸ | F9 | P00740 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | F7 | P08709 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CPS1 | P31327 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6712514 | 0.91 | F10 (0.41) | F10KCNH2F2ALDH1A1NPSR1 | |
| SCHEMBL6712477 | 0.87 | KCNH2 (0.44) | F10KCNH2F2 | |
| SCHEMBL6712468 | 0.83 | F10 (0.40) | F10KCNH2 | |
| SCHEMBL6711620 | 0.81 | KMT2A (0.33) | F10ALDH1A1 | |
| SCHEMBL6719151 | 0.78 | F10 (0.44) | F10KCNH2F2ALDH1A1 | |
| SCHEMBL6716150 | 0.75 | F10 (0.42) | F10KCNH2 | |
| SCHEMBL5549885 | 0.73 | KCNH2 (0.39) | F10KCNH2 | |
| SCHEMBL7013030 | 0.73 | F10 (0.31) | F10 | |
| SCHEMBL6711450 | 0.72 | F10 (0.45) | F10KCNH2 | |
| SCHEMBL6711451 | 0.71 | F10 (0.40) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077690-A1 | Quaternary amidino based inhibitors of factor xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1322637-A2 | QUATERNARY AMIDINO BASED INHIBITORS OF FACTOR XA | Millennium Pharmaceuticals, Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002026731-A2 | QUATERNARY AMIDINO BASED INHIBITORS OF FACTOR XA | MILLENIUM PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077690-A1 | Quaternary amidino based inhibitors of factor xa | F12, TFPI, F11 | F10 15/4885KCNH2 2891/4885F2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.